Clinical data
Trade names Optimine
AHFS/ Micromedex Detailed Consumer Information
  • US: B (No risk in non-human studies)
ATC code R06AX09 (WHO)
Legal status
Legal status
  • US: Withdrawn
CAS Number 3964-81-6 YesY
PubChem (CID) 19861
DrugBank DB00719 YesY
ChemSpider 18709 YesY
KEGG D07482 YesY
Chemical and physical data
Formula C20H22N2
Molar mass 290.402 g/mol
3D model (Jmol) Interactive image

Azatadine (Optimine) is a first-generation antihistamine and anticholinergic that was launched Schering-Plough in 1973.[1][2]

It was patented in 1967.[3] It has been succeeded by other antihistamines[4]:53 and marketing approvals have been widely withdrawn.[5][6][7][8]:290[9]

See also


  1. Katelaris, C. (1990). "Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis". Asian Pacific Journal of Allergy and Immunology. 8 (2): 103–107. PMID 1982614.
  2. Small, P.; Barrett, D.; Biskin, N. (1990). "Effects of azatadine, terfenadine, and astemizole on allergen-induced nasal provocation". Annals of allergy. 64 (2 Pt 1): 129–131. PMID 1968324.
  3. Azatadine, Villani, F. J.; Caldwell, W. U.S. Patent 3,326,924 (1967).
  4. Horak F. Antialergic and Vasoactive Drugs for Allergic Rhinitis. Chapter 4 in Allergy Frontiers:Therapy and Prevention. Volume 5 of Allergy Frontiers. Eds Pawankar R et al Springer Science & Business Media, 2010 ISBN 9784431993629
  5. listing for Azatadine Page accessed July 3, 2015
  6. Federal Register 2005 Food and Drug Administration Docket No.2005N-0058: Hospira, Inc. et al.; Withdrawal of Approval of 76 New Drug Applications and 60 Abbreviated New Drug Applications 70 FR 10651
  7. Federal Register 2007 Food and Drug Administration Docket No. 2004P-0262: Withdrawal of Approval of 128 Suitability Petitions 72 FR 8184
  8. Department of Economic and Social Affairs of the United Nations Secretariat Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals United Nations – New York, 2005
  9. FDA OGD Suitability Tracking Report (Sorted by Drug Name) Page accessed July 3, 2015

This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.